HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Lowers Price Target to $5

Benzinga Newsdesk www.benzinga.com Neutral 52.5%

Neg 0% Neu 52.5% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $7 to $5.